These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria. Skander D; Allenova A; Maurer M; Kolkhir P Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030 [No Abstract] [Full Text] [Related]
3. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria. Maurer M; Kolkhir P; Moñino-Romero S; Metz M J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668 [No Abstract] [Full Text] [Related]
4. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders? Asero R Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398 [No Abstract] [Full Text] [Related]
5. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896 [No Abstract] [Full Text] [Related]
6. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254 [No Abstract] [Full Text] [Related]
7. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab. Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792 [No Abstract] [Full Text] [Related]
8. Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria. Pedersen NH; Sørensen JA; Ghazanfar MN; Zhang DG; Vestergaard C; Thomsen SF Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511088 [TBL] [Abstract][Full Text] [Related]
10. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience. Akdaş E; Adışen E; Öztaş MO; Aksakal AB; İlter N; Gülekon A An Bras Dermatol; 2023; 98(2):240-242. PubMed ID: 36567165 [No Abstract] [Full Text] [Related]
11. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria? Thiede RM; Fazel M; MacDonald KM; Abraham I Expert Opin Pharmacother; 2022 Oct; 23(14):1563-1567. PubMed ID: 36173375 [No Abstract] [Full Text] [Related]
12. Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug. Asero R Allergy; 2018 Nov; 73(11):2242-2244. PubMed ID: 29989179 [No Abstract] [Full Text] [Related]
15. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series. Bonnekoh H; Kiefer L; Buttgereit T; Kolkhir P; Lütke-Eversloh M; Scheffel J; Maurer M; Metz M J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2578-2580.e1. PubMed ID: 37244440 [No Abstract] [Full Text] [Related]
16. Age and fast initial response predict omalizumab retreatment in chronic urticaria. Meertens MAJ; Luijf T; van Lindonk EAM; Soegiharto R; Assil S; Alizadeh Aghdam M; Kentie PA; Knulst AC; van Doorn MBA; Röckmann H J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3556-3558.e1. PubMed ID: 37517795 [No Abstract] [Full Text] [Related]
17. Omalizumab in severe chronic urticaria: are slow and non-responders different? Asero R Eur Ann Allergy Clin Immunol; 2021 Nov; 53(6):263-266. PubMed ID: 32914943 [No Abstract] [Full Text] [Related]
18. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment. Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715 [No Abstract] [Full Text] [Related]
19. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab. Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841 [No Abstract] [Full Text] [Related]
20. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count. Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]